ArticleEngineering in life sciences2025
Fab' Fragment-Immobilized Gold Surface for Capturing EpCAM-Positive Breast Cancer Cells.
Article in Engineering in life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fab' Fragment-Immobilized Gold Surface for Capturing EpCAM-Positive Breast Cancer Cells.Engineering in life sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCirculating tumor cells (CTCs) are cancer cells present in the bloodstream that originate from primary or metastatic sites. Sensitive and selective capture of these rare cells is essential for early diagnosis, metastasis prevention, and prognosis prediction. In this study, we demonstrated the effectiveness of a surface functionalized with epithelial cell adhesion molecule (EpCAM) Fab' (fragment-antigen-binding) fragments for the specific capture of EpCAM-positive human breast cancer cells. EpCAM antibody Fab' fragments were produced through pepsin digestion and characterized by SDS-PAGE analysis. Glass surfaces were silanized before being coated with a thin layer of gold via sputtering to ensure stability. The Fab' fragments were immobilized on the gold-coated glass surfaces through strong gold-thiol bonds. The modified surfaces were then characterized using Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and atomic force microscopy (AFM) analyses. Cell capture performance was assessed using fluorescence microscopy with both EpCAM-positive and EpCAM-negative cell lines. The results show that the Fab'-modified surface offers a promising platform for the selective immunocapture of EpCAM-positive cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.